v3.21.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Total revenue $ 115,533 $ 106,030
COST OF REVENUE 73,959 59,661
Total gross profit 41,574 46,369
Operating expenses:    
General and administrative 40,476 36,344
Research and development 2,456 2,060
Sales and marketing 13,749 13,258
Total operating expenses 56,681 51,662
Loss from operations (15,107) (5,293)
Interest expense, net 1,177 819
Other expense (income), net 4,854 (223)
Loss before taxes (21,138) (5,889)
Income tax expense 976 1,089
Net loss $ (22,114) $ (6,978)
NET LOSS PER SHARE    
Basic (in dollars per share) $ (0.19) $ (0.07)
Diluted (in dollars per share) $ (0.19) $ (0.07)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING    
Basic (in shares) 116,199 104,484
Diluted (in shares) 116,199 104,484
Clinical Services    
Total revenue $ 96,487 $ 92,982
Total gross profit 34,922 44,059
Pharma Services    
Total revenue 19,046 13,048
Total gross profit $ 6,652 $ 2,310

Source